MDZ Mds

MDS Pharma Services Appoints General Manager for Late Stage Development Dr. Grigore Voinov Will Have Responsibility for Central and Eastern Europe And Asia Pacific MONTREAL, Feb. 6 /PRNewswire-FirstCall/ -- MDS Pharma Services, a leading provider ofinnovative drug discovery and development solutions, has named Dr. Grigore Voinov general manager -- Central and Eastern Europe and Asia Pacific, announced Alan Morgan, vice president, Europe, Late Stage Development. While continuing to focus on growth in Eastern Europe, Voinov will develop MDS Pharma Services' global clinical development business in Asia. Currently, the company operates two late stage development facilities in this region. Its Singapore location offers central lab services and recently added global clinical development services, which should be fully established by end of year. Its state-of-the-art facility in Beijing is the first CAP-accredited lab in China and currently provides clinical support and testing for the People's Republic of China. "Dr. Voinov has experience and expertise in both establishing offices in new geographical territories and working collaboratively with partners to ensure the delivery of high quality services to our clients. This position is a great fit," said Morgan. He brings nearly 20 years of experience into this position, having served as general manager of Central and Eastern Europe (CEE) for MDS Pharma Services and CEE operations director for Phoenix International France (now part of MDS Pharma Services). He holds a Doctorate in Medicine from the University of Medicine and Pharmacy in Bucharest, Rumania. MDS Pharma Services offers a full spectrum of resources to meet the drug discovery and development needs of the pharmaceutical and biotechnology industries. With numerous facilities strategically located around the world, the company applies advanced scientific and technological expertise to each stage of the drug discovery and development process -- early stage: lead optimization, pre-IND research, pharmaceutical and biopharmaceutical development, early clinical research (bioequivalence, phases I-IIa) and bioanalysis; and late stage: global clinical development (phases IIb-IV) and central lab. For more information, visit MDS Pharma Services' Web site at http://www.mdsps.com/ . MDS Pharma Services is part of MDS Inc. (NYSE:MDZ)(TSE:MDS), an international health and life sciences company. At MDS Inc., our 10,000 highly skilled people provide services, products and instrumentsenabling health sciences organizations to enhance the well being of people around the world. We focus on helping discover and test new drugs, assisting doctors to diagnose and treat patients and preventing the spread of disease. Find out more about MDS Inc. (NYSE:MDZ)(TSE:MDS), at http://www.mdsintl.com/ or by calling 1-888-MDS-7222, 24 hours a day. DATASOURCE: MDS Pharma Services CONTACT: Kevin Langin of MDS Pharma Services, +1-402-476-2811 Web site: http://www.mdsintl.com/ http://www.mdsps.com/

Copyright